Yamada K, Donner D B
Biochem J. 1985 Jun 1;228(2):383-90. doi: 10.1042/bj2280383.
Incubation of hepatocytes from pregnant rats with dithiothreitol decreased specific 125I-prolactin (125I-prl) binding to such cells by about 20% relative to control. This was not due to a non-specific effect of dithiothreitol on the cell membrane, since reduction also altered the binding of prl to solubilized partially purified receptor. Exposure of hepatocytes to N-ethylmaleimide (6 mM) for periods as brief as 1 min decreased the subsequent specific binding of 125I-prl by more than 50%. N-Ethylmaleimide was less effective as an inhibitor of binding when applied after hepatocytes had been exposed to 125I-prl, binding being decreased by about 15%. Scatchard analysis demonstrated that the effect of N-ethylmaleimide resulted from loss of receptor-binding capacity without any substantial effect on the affinity of the prl receptor for hormone. Dithiothreitol diminished the affinity of lactogenic sites for prolactin without altering cellular binding capacity. These observations suggest that thiol and disulphide groups are present in the prl receptor and that these functional moieties regulate the formation and properties of prl receptor complexes. The species to which 125I-prl had bound were identified by affinity labelling. 125I-prl was covalently coupled into saturable complexes of Mr 65000 and 50000. 125I-human growth hormone (125I-hGH) was covalently incorporated into complexes of Mr 300 000, 220 000, 130 000, 65 000 and 50 000. Bovine growth hormone (bGH), but not prl, competed for 125I-hGH uptake into the 300 000-, 220 000- and 130 000-Mr complexes, indicating that these species were somatogenic. Prl, but not bGH, inhibited 125I-hGH uptake into 65 000- and 50 000-Mr complexes. This demonstrated that 125I-hGH in the presence of bGH could affinity-label lactogenic receptors. 125I-prl aggregates in Triton X-100, whereas 125I-hGH does not. Therefore lactogenic complexes to which 125I-hGH was bound in the presence of excess bGH were solubilized in Triton X-100 and characterized sequentially by gel filtration and affinity labelling. Prl receptors were eluted from columns of Sepharose 6B as a species of Mr380 000. Fractionation of the 380 000-Mr species on sodium dodecyl sulphate polyacrylamide gels resulted in the isolation of complexes of Mr 65 000 and 50 000. Thus non-covalent forces stabilize aggregates of the monomeric prolactin receptor.
用二硫苏糖醇孵育妊娠大鼠的肝细胞,与对照组相比,特异性125I-催乳素(125I-prl)与此类细胞的结合减少了约20%。这并非二硫苏糖醇对细胞膜的非特异性作用所致,因为还原作用也改变了prl与溶解的部分纯化受体的结合。将肝细胞暴露于N-乙基马来酰亚胺(6 mM),即使仅暴露1分钟,随后125I-prl的特异性结合也会减少50%以上。当肝细胞暴露于125I-prl后再应用N-乙基马来酰亚胺作为结合抑制剂时,效果较差,结合减少约15%。Scatchard分析表明,N-乙基马来酰亚胺的作用是由于受体结合能力丧失,而对prl受体与激素的亲和力没有实质性影响。二硫苏糖醇降低了催乳素生成位点对催乳素的亲和力,而不改变细胞结合能力。这些观察结果表明,prl受体中存在硫醇和二硫键基团,并且这些功能部分调节prl受体复合物的形成和性质。通过亲和标记鉴定了与125I-prl结合的物种。125I-prl共价偶联形成分子量为65000和50000的可饱和复合物。125I-人生长激素(125I-hGH)共价掺入分子量为300000、220000、130000、65000和50000的复合物中。牛生长激素(bGH)而非prl竞争125I-hGH进入分子量为300000、220000和130000的复合物,表明这些物种具有促生长作用。prl而非bGH抑制125I-hGH进入分子量为65000和50000的复合物。这表明在bGH存在下的125I-hGH可以亲和标记催乳素生成受体。125I-prl在Triton X-100中聚集,而125I-hGH则不会。因此,在过量bGH存在下与125I-hGH结合的催乳素生成复合物在Triton X-100中溶解,并依次通过凝胶过滤和亲和标记进行表征。Prl受体从琼脂糖6B柱上洗脱下来,为一种分子量为380000的物种。在十二烷基硫酸钠聚丙烯酰胺凝胶上对分子量为380000的物种进行分级分离,得到分子量为65000和50000的复合物。因此,非共价力稳定了单体催乳素受体的聚集体。